VYGR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -549.33% compared to Voyager Therapeutics's net margin of --. Voyager Therapeutics's return on equity of -21.07% beat Perspective Therapeutics's return on equity of --.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 314.95%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 512.35%. Given that Perspective Therapeutics has higher upside potential than Voyager Therapeutics, analysts believe Perspective Therapeutics is more attractive than Voyager Therapeutics.

Voyager Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87699999999999% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are larger than Perspective Therapeutics quarterly revenues of --. Voyager Therapeutics's net income of -$34.5M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.80x versus 13.34x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -2.16%. Voyager Therapeutics's return on equity of -21.07% beat Myomo's return on equity of -48.64%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 314.95%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 67.57%. Given that Voyager Therapeutics has higher upside potential than Myomo, analysts believe Voyager Therapeutics is more attractive than Myomo.

Voyager Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87699999999999% less volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Voyager Therapeutics's net income of -$34.5M is lower than Myomo's net income of -$260.1K. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.80x versus 6.40x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -30.91%. Voyager Therapeutics's return on equity of -21.07% beat PTC Therapeutics's return on equity of --.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 314.95%. On the other hand PTC Therapeutics has an analysts' consensus of $64.93 which suggests that it could grow by 13.85%. Given that Voyager Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Voyager Therapeutics is more attractive than PTC Therapeutics.

Voyager Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87699999999999% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Voyager Therapeutics's net income of -$34.5M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.80x versus 5.43x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -549.33% compared to Voyager Therapeutics's net margin of -296.76%. Voyager Therapeutics's return on equity of -21.07% beat Zevra Therapeutics's return on equity of -208.85%.

Voyager Therapeutics has a consensus price target of $16.10, signalling upside risk potential of 314.95%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 169.98%. Given that Voyager Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Voyager Therapeutics is more attractive than Zevra Therapeutics.

Voyager Therapeutics has a beta of 0.991, which suggesting that the stock is 0.87699999999999% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.977, suggesting its more volatile than the S&P 500 by 97.719%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $6.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Voyager Therapeutics's net income of -$34.5M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Voyager Therapeutics's price-to-earnings ratio is 6.11x while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 2.80x versus 15.69x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.